



STARS

STRENGTHENING
REGULATORY
SCIENCE

Second European Stakeholder Workshop: Summary, conclusion and outlook

Dr. Wiebke Löbker (BfArM)
STARS Coordination

Second European Stakeholder Workshop
November 17th/18th, 2021



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825881

Classified as internal/staff & contractors by the European Medicines Agency



(1) Regulatory authorities in Europe (EMA & NCAs)

- #1 Provision and regular update of **targeted information material** about the regulatory framework and legal approval procedures in place
- #2 Use of **appropriate media channels** to reach out to academia
- #3 Communication and **networking events**
- #4 **Low threshold access** to regulatory authorities
- #5 Increase of awareness and use of **regulatory support tools**
- #6 Support in the **preparation of scientific advice** for academia
- #7 **Low threshold to apply** for regulatory advice
- #8 **Expanding and promoting existing structures** within NCAs
- #9 **Harmonisation** of the regulatory processes between the member states (standardised forms and processes as well as mutual online service platforms)

(2) Academic Researchers and Institutions (e.g. Universities & Research Institutes)

- #10 Optimize **engagement and collaboration** of academia
- #11 Encouraging **compliance with clinical trial** results reporting requirements on EudraCT
- #12 **Early communication** with regulators and HTA before starting research project.

(3) European Commission, Ministries and Funders (e.g. RTD & Research and Health Ministries as well as other funders)

- #13 Introduction and **implementation of regulatory needs and aspects** for funded biomedical research projects
- #14 **Monitoring compliance** with regulatory affairs during the project
- #15 **Sustainability** of the STARS achievements and tools
- #16 **Support of research of regulatory processes** by specific funding measures
- #17 Implementation of a **pre-grant advice**

(4) Industry (e.g. Pharmaceutical & Biomedical)

- #18 The **early contact** and dialogue between academic researchers/institutions and start-ups, small medium enterprises and industry should be fostered reciprocal

(5) Education (e.g. Universities & Regulatory Authorities)

- #19 **Continuous education and training of regulators**
- #20 **Continuous regulatory training of the academia**

(6) Cross-cutting Recommendations

- #21 Consideration of lessons learned in regulatory science, procedures and guidelines **beyond Europe**, e.g. along with the STARS global conference in 2022

Now that we've discussed all the recommendations, which three are the most important to you?

17 Implementation of a pre-grant advice




04 Low threshold access to regulatory authorities



05 Increase of awareness and use of regulatory support tools



Outlook





STARS

STRENGTHENING
REGULATORY
SCIENCE



Thank you!

... to all participants, panelists, moderators,
notetakers, rapporteurs, supporters, impulse givers, ...

...and especially to Anne Heß (BfArM/STARS coordination)
&
Hanneke Parkinson & EMA team for preparing this event!



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825881

Classified as internal/staff & contractors by the European Medicines Agency